Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Instituto do Cancer do Estado de São Paulo
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
AstraZeneca
Pfizer
Pfizer
Stanford University
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
University of Colorado, Denver
University of Nebraska
Zhejiang University
Adela, Inc
RenJi Hospital
Degron Therapeutics Co.
Jonsson Comprehensive Cancer Center
Azienda Ospedaliera di Padova
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Columbia University
Nanjing First Hospital, Nanjing Medical University